

INTRAVASCULAR DELIVERY OF MIZORIBINE

ABSTRACT OF THE DISCLOSURE

The present invention provides improved devices and methods for minimizing
5 and/or inhibiting restenosis and hyperplasia after intravascular intervention. In particular, the
present invention provides luminal prostheses which allow for programmed and controlled
mizoribine delivery with increased efficacy to selected locations within a patient's
vasculature to inhibit restenosis. An intraluminal delivery prosthesis may comprise an
expansible structure and means on or within the structure for releasing mizoribine into the
10 body lumen to inhibit smooth muscle cell proliferation.

PA 3126159 v1

15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500